Browse the evidence

Average weight loss was 1.3kg (SD 2.3, P=0.03).

Weight loss can be achieved through mindful eating interventions using technology.

77% reported improving three or more consumption behaviors.

Encouraging multiple behavior changes can enhance the effectiveness of dietary interventions.

Twins on the healthy vegan diet had a greater reduction in LDL cholesterol after 8 weeks compared to those on the healthy omnivorous diet (-15.2 vs. -2.3 mg/dL).

A vegan diet may be more effective than an omnivorous diet for lowering LDL cholesterol.

Participants on the healthy vegan diet lost more body weight after 8 weeks compared to those on the healthy omnivorous diet (-1.9 vs. -0.29 kg).

Adopting a vegan diet may facilitate greater weight loss compared to an omnivorous diet.

The iDiet prioritizes hunger suppression more than other conventional behavioral programs.

Practitioners should consider the iDiet's emphasis on hunger suppression when advising clients.

The iDiet includes behavioral support to change food preferences and decrease food cravings.

Practitioners can use the iDiet's approach to help clients manage cravings and food preferences.

The GLP-1 receptor agonist Semaglutide and the GIPR/GLP-1R co-agonist Tirzepatide lead to a weight loss greater than 10%.

Practitioners can consider Semaglutide and Tirzepatide as effective options for weight management in patients with obesity and Type 2 diabetes.

Higher adherence to whole food plant-based (WFPB) and vegan diets is significantly associated with lower BMI.

Encouraging adherence to WFPB and vegan diets may help individuals achieve lower body weight.

Fully plant-based diets (WFPB and vegan) have the healthiest Healthy Eating Index (HEI) scores and BMIs.

Promoting fully plant-based diets may lead to improved diet quality and health outcomes.

Pharmacotherapy is an important adjunct to lifestyle and behavioral modifications in obesity management.

Practitioners should consider pharmacotherapy for patients struggling with weight loss despite lifestyle changes.

FDA-approved anti-obesity medications can facilitate weight loss and enhance metabolic indices.

Practitioners can recommend these medications for weight management in obese patients.

The reduction of excess body fat is crucial for the treatment of type 2 diabetes.

Weight loss strategies should be prioritized in diabetes management plans.

The study cohort lost an average of 23% of their BMI from baseline.

Weight loss programs can lead to significant reductions in BMI among employees.

At the end of the one-year course, 18 participants reduced their weight by an average of 8.6% from their initial weight.

Weight reduction programs focusing on coping strategies for carbohydrate avoidance can be effective.

18 participants reduced their weight by an average of 8.6% from baseline after a one-year course focused on coping strategies for low carbohydrate intake.

Practitioners can implement similar group courses focusing on coping strategies for low carbohydrate diets to aid weight loss.

The course is proposed as an easily applicable method to address obesity in specialized settings.

This approach can be integrated into obesity treatment programs in various healthcare settings.

Obesity is a primary driver for the development of type 2 diabetes.

Weight loss interventions should be prioritized in managing patients with type 2 diabetes.

The treatment of obesity includes lifestyle modifications, pharmacological interventions, and surgical procedures.

Practitioners should implement a multifaceted approach to obesity treatment.

Obesity is recognized as a chronic, progressive condition requiring early intervention and long-term management.

Practitioners should prioritize early intervention and long-term strategies in managing obesity.

The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance.

Weight loss medications should be viewed as tools for achieving and maintaining weight loss.

The position statement includes recommendations on the overall management of obesity.

Healthcare providers should utilize these recommendations to improve obesity management.

The treatment of obesity requires a multifaceted approach, including lifestyle interventions, pharmacological treatments, and bariatric surgery.

Practitioners should implement a combination of lifestyle changes, medications, and consider surgical options for effective obesity treatment.

GLP-1 agonists such as liraglutide and semaglutide are more efficacious than other approved drugs in weight management therapy.

Practitioners may consider GLP-1 agonists as a preferred option for weight management in diabetic patients.

Tirzepatide reduces fasting and postprandial glucose levels, food consumption, and body weight in people with type 2 diabetes.

Tirzepatide may be an effective treatment option for managing blood glucose and weight in type 2 diabetes patients.